Virtus Investment Advisers Inc. Buys New Shares in Bausch Health Companies Inc. (NYSE:BHC)

Virtus Investment Advisers Inc. acquired a new stake in Bausch Health Companies Inc. (NYSE:BHC - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 92,700 shares of the company's stock, valued at approximately $747,000.

A number of other hedge funds have also recently bought and sold shares of BHC. Maple Rock Capital Partners Inc. boosted its position in Bausch Health Companies by 156.7% in the 4th quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock valued at $42,718,000 after buying an additional 3,235,100 shares during the last quarter. Compass Rose Asset Management LP boosted its position in Bausch Health Companies by 366.7% in the 4th quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company's stock valued at $16,926,000 after buying an additional 1,650,000 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Bausch Health Companies by 46.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock valued at $38,501,000 after purchasing an additional 1,510,445 shares during the period. SG Americas Securities LLC lifted its stake in shares of Bausch Health Companies by 62.0% in the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock valued at $26,614,000 after purchasing an additional 1,263,706 shares during the period. Finally, O Shaughnessy Asset Management LLC lifted its stake in shares of Bausch Health Companies by 989.1% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 611,890 shares of the company's stock valued at $4,940,000 after purchasing an additional 555,709 shares during the period. 78.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Wall Street Zen downgraded Bausch Health Companies from a "buy" rating to a "hold" rating in a research note on Saturday, May 10th. Finally, Royal Bank of Canada increased their price target on Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $7.42.

Bausch Health Companies Stock Performance

BHC stock traded up $0.02 during midday trading on Thursday, hitting $4.50. 1,047,036 shares of the company's stock were exchanged, compared to its average volume of 2,583,284. The stock's fifty day moving average price is $5.41 and its 200-day moving average price is $6.89. The company has a market cap of $1.63 billion, a PE ratio of -37.50, a price-to-earnings-growth ratio of 0.37 and a beta of 0.34. Bausch Health Companies Inc. has a one year low of $3.96 and a one year high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The firm had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. On average, analysts expect that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.